Vadadustat shows significant reduction in mortality and hospitalization in CKD anemia patients on dialysis.

Akebia Therapeutics announced that a post-hoc analysis of its Phase 3 INNO2VATE trial showed vadadustat significantly reduced the combined risk of death and hospitalization compared to darbepoetin alfa in patients with anemia due to chronic kidney disease (CKD) on dialysis. Published in the Journal of the American Society of Nephrology, this analysis supports vadadustat's clinical benefits and potential as a standard treatment for dialysis-dependent CKD anemia. Vadadustat (Vafseo®) is already approved in the U.S. for this use, and the company aims to increase its adoption among healthcare providers.